TScan Therapeutics (TCRX) Change in Accured Expenses (2020 - 2025)
Historic Change in Accured Expenses for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$1.1 million.
- TScan Therapeutics' Change in Accured Expenses fell 31062.62% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189000.0, marking a year-over-year decrease of 10866.57%. This contributed to the annual value of $4.5 million for FY2024, which is 1762.26% up from last year.
- Latest data reveals that TScan Therapeutics reported Change in Accured Expenses of -$1.1 million as of Q3 2025, which was down 31062.62% from $2.7 million recorded in Q2 2025.
- In the past 5 years, TScan Therapeutics' Change in Accured Expenses ranged from a high of $3.7 million in Q4 2024 and a low of -$5.4 million during Q1 2025
- For the 5-year period, TScan Therapeutics' Change in Accured Expenses averaged around $447368.4, with its median value being $783000.0 (2023).
- In the last 5 years, TScan Therapeutics' Change in Accured Expenses surged by 19982.49% in 2021 and then plummeted by 31736.77% in 2024.
- Quarter analysis of 5 years shows TScan Therapeutics' Change in Accured Expenses stood at $1.8 million in 2021, then fell by 28.37% to $1.3 million in 2022, then decreased by 0.91% to $1.3 million in 2023, then skyrocketed by 179.33% to $3.7 million in 2024, then tumbled by 130.31% to -$1.1 million in 2025.
- Its Change in Accured Expenses was -$1.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and -$5.4 million in Q1 2025.